TY - JOUR
T1 - The distinctive biology of cancer in adolescents and young adults
AU - Bleyer, Archie
AU - Barr, Ronald
AU - Hayes-Lattin, Brandon
AU - Thomas, David
AU - Ellis, Chad
AU - Anderson, Barry
N1 - Funding Information:
Author contributions are as follows: Study concept and design: A.B. Acquisition of data: A.B. Analysis and interpretation of data: A.B. Drafting of the manuscript: A.B., R.B. Critical revision of the manuscript for intellectual content: A.B., R.B., B.A., B.H.-L., D.T. and C.E. Statistical expertise: A.B. Obtained funding: A.B. Authors who are independent of any commercial funder and had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis: A.B., R.B., B.A., B.H.-L., D.T. and C.E. Administrative, technical or material support: A.B. Study supervision: A.B. This work was supported by grants from the Aflac Insurance Co., the National Cancer Institute (NCI U10 CA98543) and the Lance Armstrong Foundation. Presented in part at the Roundtable Meeting of the National Cancer Institute Progress Review Group, Denver, Colorado, 24–25 April, 2006. We are indebted to the members of the Children’s Oncology Group Adolescent and Young Adult Committee and the Aflac Insurance Co. for their support of and contributions to this investigation. The Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology are M. Tewari, L. Balducci, C. Bloomfield, W. Carroll, D. Colaizzi, Robert Comis, G. D’Amato, M. Foti, J. Goldberg, D. Hawkins, M. L. Keohan, M. Link, C. Love, B. Rubin, P. Shaw, C. Somkin, W. Stock, J. Summers, D. Sussman, S. Wells, J. Whelan and B. Williams.
PY - 2008/4
Y1 - 2008/4
N2 - One explanation for the relative lack of progress in treating cancer in adolescents and young adults is that the biology of malignant diseases in this age group is different than in younger and older persons, not only in the spectrum of cancers but also within individual cancer types and within the patient (host). Molecular, epidemiological and therapeutic outcome comparisons offer clues to this distinctiveness in most of the common cancers of adolescents and young adults. Translational and clinical research should not assume that the biology of cancers and patients is the same as in other age groups, and treatment strategies should be tailored to the differences.
AB - One explanation for the relative lack of progress in treating cancer in adolescents and young adults is that the biology of malignant diseases in this age group is different than in younger and older persons, not only in the spectrum of cancers but also within individual cancer types and within the patient (host). Molecular, epidemiological and therapeutic outcome comparisons offer clues to this distinctiveness in most of the common cancers of adolescents and young adults. Translational and clinical research should not assume that the biology of cancers and patients is the same as in other age groups, and treatment strategies should be tailored to the differences.
UR - http://www.scopus.com/inward/record.url?scp=41149119450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41149119450&partnerID=8YFLogxK
U2 - 10.1038/nrc2349
DO - 10.1038/nrc2349
M3 - Review article
C2 - 18354417
AN - SCOPUS:41149119450
SN - 1474-175X
VL - 8
SP - 288
EP - 298
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 4
ER -